Patrick T Griffin1, Viet Q Ho2, William Fulp3, Taiga Nishihori4, Kenneth H Shain1, Melissa Alsina4, Rachid C Baz1. 1. Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 2. Department of Pharmacy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 3. Department of Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. 4. Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Abstract
BACKGROUND: Despite the impact of proteasome inhibitors and immunomodulatory agents, infusional chemotherapy regimens continue to be used for patients with multiple myeloma. To the authors' knowledge, contemporary data regarding salvage chemotherapy regimens are sparse, with no direct comparisons. METHODS: The authors performed a single-institution study comparing 3 salvage chemotherapy regimens in 107 patients with recurrent/refractory multiple myeloma: dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) in 52 patients; bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide (VTD-PACE) in 22 patients; and cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) in 33 patients. RESULTS: Differences between treatment groups existed, including higher baseline creatinine for patients treated with CVAD (P<.001) and greater prior use of infusional chemotherapy for those receiving VTD-PACE (P<.001). There was no significant difference in response noted among the 3 regimens: 55% overall (P = .18). For the intent-to-transplant population, a similar percentage were successfully bridged to transplant without further therapy (62%; P = .9). There was no difference in survival observed across the 3 regimens, with an overall median progression-free survival of 4.5 months (95% confidence interval, 3.6-5.5 months [P = .8]) and a median overall survival of 8.5 months (95% confidence interval, 6.1-11 months [P = .8]). Furthermore, there was no statistically significant difference noted among clinically relevant adverse events, although there was a suggestion of fewer adverse events with DCEP. Patients treated with the intent to transplant had superior outcomes for response (odds ratio, 3.40; P = .01), progression-free survival (hazard ratio, 0.28; P<.001), and overall survival (hazard ratio, 0.19; P<.001). CONCLUSIONS: The 3 salvage regimens demonstrated similar responses, survival, and adverse events. Given the short response durations observed in the recurrent/refractory disease setting, infusional chemotherapy is best suited for cytoreduction before more definitive therapy is administered.
BACKGROUND: Despite the impact of proteasome inhibitors and immunomodulatory agents, infusional chemotherapy regimens continue to be used for patients with multiple myeloma. To the authors' knowledge, contemporary data regarding salvage chemotherapy regimens are sparse, with no direct comparisons. METHODS: The authors performed a single-institution study comparing 3 salvage chemotherapy regimens in 107 patients with recurrent/refractory multiple myeloma: dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) in 52 patients; bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide (VTD-PACE) in 22 patients; and cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD) in 33 patients. RESULTS: Differences between treatment groups existed, including higher baseline creatinine for patients treated with CVAD (P<.001) and greater prior use of infusional chemotherapy for those receiving VTD-PACE (P<.001). There was no significant difference in response noted among the 3 regimens: 55% overall (P = .18). For the intent-to-transplant population, a similar percentage were successfully bridged to transplant without further therapy (62%; P = .9). There was no difference in survival observed across the 3 regimens, with an overall median progression-free survival of 4.5 months (95% confidence interval, 3.6-5.5 months [P = .8]) and a median overall survival of 8.5 months (95% confidence interval, 6.1-11 months [P = .8]). Furthermore, there was no statistically significant difference noted among clinically relevant adverse events, although there was a suggestion of fewer adverse events with DCEP. Patients treated with the intent to transplant had superior outcomes for response (odds ratio, 3.40; P = .01), progression-free survival (hazard ratio, 0.28; P<.001), and overall survival (hazard ratio, 0.19; P<.001). CONCLUSIONS: The 3 salvage regimens demonstrated similar responses, survival, and adverse events. Given the short response durations observed in the recurrent/refractory disease setting, infusional chemotherapy is best suited for cytoreduction before more definitive therapy is administered.
Authors: Emma C Scott; Richard T Maziarz; Stephen E Spurgeon; Eva Medvedova; James Gajewski; Shara Reasor-Heard; Byung Park; Anne Kratz; George V Thomas; Marc Loriaux; Michael Cascio; Jennifer Podolak; Miranda Gordon; Jennifer Botelho; Edward Stadtmauer; Ravi Amaravadi; Dan T Vogl Journal: Haematologica Date: 2017-04-06 Impact factor: 9.941
Authors: Scott R Goldsmith; Mark A Fiala; Brandon Wang; Mark A Schroeder; Tanya M Wildes; Armin Ghobadi; Keith Stockerl-Goldstein; Ravi Vij Journal: Ann Hematol Date: 2020-03-04 Impact factor: 3.673
Authors: Samer Tabchi; Rajit Nair; Chutima Kunacheewa; Krina K Patel; Hans C Lee; Sheeba K Thomas; Behrang Amini; Sairah Ahmed; Rohtesh S Mehta; Qaiser Bashir; Muzzaffar H Qazilbash; Donna M Weber; Robert Z Orlowski; Raymond Alexanian; Lei Feng; Elisabet E Manasanch Journal: Clin Lymphoma Myeloma Leuk Date: 2019-05-17